Amerikanische Gesellschaft für Hirudotherapie

Treatment of deep cavities using a perforator-based island flap with partial de-epithelization

Case series published in BMC Surg (2018)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienChang JW et al. · BMC surgery, 2018

Abstract

BACKGROUND: The perforator-based island flap is a popular option for defect coverage. In cases with deep cavities, however, the classical island flap may not be a suitable option. By de-epithelization of the peripheral portion of a perforator-based island flap, the distal part of the flap can be used to fill deep spaces, as the flap can be folded and inserted into the spaces. METHODS: From June 2015 to April 2017, 21 cases of deep internal defects were reconstructed with perforator-based island flaps with peripheral de-epithelization. A fasciocutaneous flap was elevated and rotated with the pivot point on the perforator. After performing de-epithelization on the periphery of the flap, the de-epithelized portion of the flap was inserted and anchored into the internal defect. Demographic information about the patients, the size of the defects, the perforators that were used, and complications were recorded. RESULTS: During the follow-up period (mean, 14.2 months) of total 21 cases, no major complications such as flap loss occurred. In 2 cases, a minor complication was observed. Temporary flap congestion was seen in 1 case, and was treated with a short period of leech therapy, and the other case was partial necrosis on the flap margin, which was cured with minimal debridement and conservative treatment. No major problems have occurred, especially on the de-epithelized part of the flap and in the occupied space. CONCLUSIONS: With performing careful procedure, a perforator-based island flap with partial de-epithelization can be a useful option for the surgical treatment of deep cavities. TRIAL REGISTRATION: This study was retrospectively registered in the institutional review board on human subjects research and the ethics committee, Hanyang University Guri Hospital (Institutional Review Board File No. 2018-01-003-002 https://www.e-irb.com:3443/devlpg/nlpgS200.jsp ).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAgedAged, 80 and overDebridementFemaleHumansMaleMiddle AgedNecrosisPerforator FlapPostoperative ComplicationsPlastic Surgery Procedures

Zusammenfassung

21 cases of deep internal-defect reconstruction with perforator-based de-epithelized island flaps. Temporary flap congestion treated with short course of leech therapy. No major complications.

Warum dies für die Hirudotherapie relevant ist

This study reviewed 21 cases of deep cavity reconstruction using perforator-based island flaps with partial de-epithelization, reporting no major complications over a mean 14.2-month follow-up. One case of temporary flap congestion was treated with a short period of leech therapy, and one case of marginal partial necrosis healed with conservative management. This is relevant to ASH's domain as it documents leech therapy used successfully as a salvage measure for flap congestion in perforator-based island reconstruction. The honest caveat is that leeching was a minor single-instance event within a surgical technique study, no details about leeching protocol, duration, or species are provided, and the abstract's primary focus is flap design rather than hirudotherapy outcomes.

Zitation

Treatment of deep cavities using a perforator-based island flap with partial de-epithelization.

Chang JW et al. · BMC surgery, 2018

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.